You are here

Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

Last updated on February 23, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-45 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Medical History

1. Presence or history of any disorder that may prevent the successful completion of the
study.

2. Any unstable medical condition.

3. History of seizures.

4. History of cardiac disorders (other than hypertension) including but not limited to
valvular disease, congestive heart failure, angina pectoris, myocardial infarction, or
arrhythmia.

5. Any significant cardiovascular disease, hepatic, renal, respiratory, gastrointestinal,
endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

6. Any surgical or medical condition that may interfere with the absorption,
distribution, metabolism, or excretion of the test article (eg, resection of liver,
kidney, gallbladder, or gastrointestinal tract).

7. Acute disease state (eg, nausea, vomiting, infection, fever, or diarrhea) within 7
days before study day 1).

8. History of drug abuse within 1 year before study day 1.

9. Admitted alcohol abuse or history of alcohol use that may interfere with the subject's
ability to comply with the protocol requirements.

Physical and Laboratory Findings

10. Clinically significant electrocardiogram (ECG) abnormalities.

11. Any clinically important deviation from normal limits in physical examination
findings, vital sign measurements, 12-lead ECGs, or clinical laboratory test results.

12. Positive serologic findings for human immunodeficiency virus (HIV) antigen and
antibodies, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV)
antibodies.

13. Positive findings of urine drug screen (eg, amphetamines, barbiturates,
benzodiazepines, cannabinoids, cocaine, opiates, and phencyclidine [PCP]).

14. Troponin T or CK-MB levels above reference range at screening. Allergies and Adverse
Drug Reactions

15. History of any clinically important drug allergy (eg, relapsing dermatitis, drug
hypersensitivity, drug allergy, hypersensitivity to ingredient in the test articles,
angioedema).

Prohibited Treatments

16. Use of any investigational drug within 90 days before study day 1 or prescription drug
within 30 days before study day 1.

17. Tobacco use or the consumption of any caffeine-containing products (eg, coffee, tea,
chocolate, or carbonated beverages) or alcoholic beverages within 72 hours before
study day 1 until the end of the inpatient confinement period.

18. Consumption of grapefruit or grapefruit-containing products within 72 hours before
study day 1 until the end of the inpatient confinement period.

19. Use of any over-the-counter drugs, including herbal supplements (except for the
occasional use of vitamins ?100% of the recommended daily allowance), within 14 days
before study day 1 (St. John wort is prohibited within 30 days of study day 1).

20. Donation of blood within 90 days before study day 1. Others

21. Subjects deemed by the investigator to be inappropriate according to the inclusion
criteria in the study and according to the screening examination.

NCT01268124
Pfizer
Completed
Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now